NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Atossa Therapeutics, Inc. ATOS
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-4.04
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-62.7%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -4.04
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-62.7%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-56.1%
Each USD of equity lost 63 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−84.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 47.6M
total assets, end of FY2025
Total assetsUSD 47.6M
EquityUSD 39.4M
CashUSD 41.3M
Current ratio5.53×
Equity funds 83% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
·
·
·
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−4.04
−3.04
−0.24
−0.21
−0.18
−1.97
−2.03
−5.50
−10.97
−2.16
−8.31
−0.61
−0.70
−0.41
−0.38
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−62.7
−31.4
−28.8
−21.1
−24.9
−88.4
−157.0
−144.9
−161.9
−186.3
−238.1
−145.9
−136.7
−150.8
−972.6
·
Shares out B
0.01
0.01
0.13
0.13
0.13
0.05
0.01
0.01
0.00
0.00
0.00
0.02
0.02
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 50
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 2 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed